^
Contact us to learn more about
our Premium Content: News alerts, weekly reports and conference plannersDRUG:
tobemstomig (RG6139)
i
Other names: RG6139, RO7247669, PD1-LAG3 BsAb, RG 6139, RO 7247669, RG-6139, RO-7247669
Contact us to learn more about our Premium Content:
News alerts, weekly reports and conference planners
Company:
Roche
Drug class:
PD1 inhibitor, LAG-3 inhibitor
Related drugs:
5d
A Study Evaluating Different Immunotherapies (LAG-3 and PD-1 With or Without TIGIT, Compared to PD-L1 Alone) in Participants With Untreated Locally Advanced Metastatic Urothelial Cancer (clinicaltrials.gov)
P2, N=210, Active, not recruiting, Hoffmann-La Roche | Recruiting --> Active, not recruiting
Enrollment closed
|
PD-L1 (Programmed death ligand 1)
|
Tecentriq (atezolizumab) • tiragolumab (RG6058) • tobemstomig (RG6139)
2ms
Dose Escalation Study of a PD1-LAG3 Bispecific Antibody in Patients With Advanced and/or Metastatic Solid Tumors (clinicaltrials.gov)
P1/2, N=320, Active, not recruiting, Hoffmann-La Roche | Recruiting --> Active, not recruiting
Enrollment closed
|
PD-L1 expression
|
tobemstomig (RG6139)
2ms
A Study of Immune Checkpoint Inhibitor Combinations With Axitinib in Participants With Untreated Locally Advanced Unresectable or Metastatic Renal Cell Carcinoma (clinicaltrials.gov)
P2, N=210, Active, not recruiting, Hoffmann-La Roche | Recruiting --> Active, not recruiting | Trial completion date: Mar 2026 --> Oct 2026 | Trial primary completion date: Sep 2024 --> May 2025
Enrollment closed • Trial completion date • Trial primary completion date • Checkpoint inhibition • Metastases
|
Keytruda (pembrolizumab) • Inlyta (axitinib) • tiragolumab (RG6058) • tobemstomig (RG6139)
3ms
A Study of Multiple Doses of RO7247669 in Participants With Previously Untreated Unresectable or Metastatic Melanoma (clinicaltrials.gov)
P2, N=80, Recruiting, Hoffmann-La Roche | Phase classification: P1/2 --> P2
Phase classification
|
PD-L1 (Programmed death ligand 1) • BRAF (B-raf proto-oncogene)
|
tobemstomig (RG6139)
6ms
A Study Evaluating the Efficacy and Safety of Multiple Immunotherapy-Based Treatment Combinations in Patients With Advanced Liver Cancers (Morpheus-Liver) (clinicaltrials.gov)
P1/2, N=506, Recruiting, Hoffmann-La Roche | Trial completion date: Dec 2025 --> Aug 2026 | Trial primary completion date: Dec 2025 --> Aug 2026
Trial completion date • Trial primary completion date
|
PD-L1 (Programmed death ligand 1)
|
Avastin (bevacizumab) • Tecentriq (atezolizumab) • amezalpat (TPST-1120) • Actemra IV (tocilizumab) • tiragolumab (RG6058) • NKT2152 • muzastotug (ADG126) • tobemstomig (RG6139)
7ms
A Study of Tobemstomig Plus Platinum-Based Chemotherapy vs Pembrolizumab Plus Platinum-Based Chemotherapy in Participants With Previously Untreated Non-Small Cell Lung Cancer (clinicaltrials.gov)
P2, N=180, Recruiting, Hoffmann-La Roche | Active, not recruiting --> Recruiting
Enrollment open • Metastases
|
PD-L1 (Programmed death ligand 1)
|
Keytruda (pembrolizumab) • carboplatin • paclitaxel • pemetrexed • tobemstomig (RG6139)
7ms
A Study Evaluating the Efficacy and Safety of Multiple Treatment Combinations in Patients With Melanoma (Morpheus-Melanoma) (clinicaltrials.gov)
P1/2, N=110, Completed, Hoffmann-La Roche | Recruiting --> Completed | N=336 --> 110 | Trial completion date: Jul 2025 --> Mar 2024 | Trial primary completion date: Jan 2025 --> Sep 2023
Trial completion • Enrollment change • Trial completion date • Trial primary completion date
|
CD4 (CD4 Molecule)
|
Opdivo (nivolumab) • Tecentriq (atezolizumab) • Yervoy (ipilimumab) • tiragolumab (RG6058) • tobemstomig (RG6139)
7ms
A Study of Tobemstomig Plus Platinum-Based Chemotherapy vs Pembrolizumab Plus Platinum-Based Chemotherapy in Participants With Previously Untreated Non-Small Cell Lung Cancer (clinicaltrials.gov)
P2, N=180, Active, not recruiting, Hoffmann-La Roche | Recruiting --> Active, not recruiting
Enrollment closed • Metastases
|
PD-L1 (Programmed death ligand 1)
|
Keytruda (pembrolizumab) • carboplatin • paclitaxel • pemetrexed • tobemstomig (RG6139)
9ms
A Study Evaluating The Efficacy and Safety of Neoadjuvant Immunotherapy Combinations in Patients With Surgically Resectable Hepatocellular Carcinoma (clinicaltrials.gov)
P1/2, N=150, Recruiting, Hoffmann-La Roche | Trial completion date: Feb 2027 --> Sep 2028 | Trial primary completion date: May 2025 --> Sep 2025
Trial completion date • Trial primary completion date
|
Avastin (bevacizumab) • Tecentriq (atezolizumab) • tiragolumab (RG6058) • tobemstomig (RG6139)
12ms
A Study of Multiple Doses of RO7247669 in Participants With Previously Untreated Unresectable or Metastatic Melanoma (clinicaltrials.gov)
P1/2, N=80, Recruiting, Hoffmann-La Roche | Phase classification: P2 --> P1/2
Phase classification • Metastases
|
PD-L1 (Programmed death ligand 1) • BRAF (B-raf proto-oncogene)
|
BRAF mutation • BRAF V600
|
tobemstomig (RG6139)
over1year
A Study Evaluating the Efficacy and Safety of Multiple Treatment Combinations in Patients With Melanoma (Morpheus-Melanoma) (clinicaltrials.gov)
P1/2, N=336, Recruiting, Hoffmann-La Roche | Trial primary completion date: Oct 2024 --> Jan 2025
Trial primary completion date
|
CD4 (CD4 Molecule)
|
Opdivo (nivolumab) • Tecentriq (atezolizumab) • Yervoy (ipilimumab) • tiragolumab (RG6058) • tobemstomig (RG6139)
over1year
A global, multicentre, open-label, randomised phase II trial of tobemstomig (tobe) with or without tiragolumab (tira) vs atezolizumab (atezo) in patients (pts) with untreated metastatic urothelial cancer (mUC) ineligible for platinum-based chemotherapy (chemo) (ESMO 2023)
This study will evaluate the effect of tobe and tobe + tira on investigator-assessed confirmed ORR (primary endpoint) relative to atezo. Secondary endpoints include PFS, OS, DOR, DCR and safety.
P2 data • Clinical • PD(L)-1 Biomarker • IO biomarker • Metastases
|
LAG3 (Lymphocyte Activating 3) • TIGIT (T Cell Immunoreceptor With Ig And ITIM Domains 2)
|
PD-L1 expression
|
VENTANA PD-L1 (SP263) Assay
|
Tecentriq (atezolizumab) • tiragolumab (RG6058) • tobemstomig (RG6139)
over1year
A Study Evaluating the Efficacy and Safety of Multiple Treatment Combinations in Patients With Melanoma (Morpheus-Melanoma) (clinicaltrials.gov)
P1/2, N=336, Recruiting, Hoffmann-La Roche | N=191 --> 336 | Trial completion date: Mar 2024 --> Jul 2025 | Trial primary completion date: Nov 2023 --> Oct 2024
Enrollment change • Trial completion date • Trial primary completion date
|
CD4 (CD4 Molecule)
|
Opdivo (nivolumab) • Tecentriq (atezolizumab) • Yervoy (ipilimumab) • tiragolumab (RG6058) • tobemstomig (RG6139)
over1year
A Study of Lomvastomig (RO7121661) and Tobemstomig (RO7247669) Compared With Nivolumab in Participants With Advanced or Metastatic Squamous Cell Carcinoma of the Esophagus (clinicaltrials.gov)
P2, N=210, Active, not recruiting, Hoffmann-La Roche | Recruiting --> Active, not recruiting
Enrollment closed • IO biomarker • Metastases
|
CD8 (cluster of differentiation 8) • PD-1 (Programmed cell death 1) • LAG3 (Lymphocyte Activating 3) • HAVCR2 (Hepatitis A Virus Cellular Receptor 2) • CD4 (CD4 Molecule)
|
CD8 expression • LAG3 expression
|
Opdivo (nivolumab) • lomvastomig (RG7769) • tobemstomig (RG6139)
over1year
A Study Evaluating The Efficacy and Safety of Neoadjuvant Immunotherapy Combinations in Patients With Surgically Resectable Hepatocellular Carcinoma (clinicaltrials.gov)
P1/2, N=150, Not yet recruiting, Hoffmann-La Roche
New P1/2 trial
|
Avastin (bevacizumab) • Tecentriq (atezolizumab) • tiragolumab (RG6058) • tobemstomig (RG6139)
over1year
A Study of RO7247669 + Nab-Paclitaxel Compared With Pembrolizumab + Nab-Paclitaxel in Participants With Previously Untreated, PD-L1-Positive, Locally-Advanced Unresectable or Metastatic Triple-Negative Breast Cancer (clinicaltrials.gov)
P2, N=160, Recruiting, Hoffmann-La Roche | Not yet recruiting --> Recruiting
Enrollment open • Metastases
|
HER-2 (Human epidermal growth factor receptor 2) • PD-L1 (Programmed death ligand 1) • ER (Estrogen receptor) • CD4 (CD4 Molecule)
|
PD-L1 expression • PGR expression
|
Keytruda (pembrolizumab) • albumin-bound paclitaxel • tobemstomig (RG6139)
over1year
A Study of RO7247669 + Nab-Paclitaxel Compared With Pembrolizumab + Nab-Paclitaxel in Participants With Previously Untreated, PD-L1-Positive, Locally-Advanced Unresectable or Metastatic Triple-Negative Breast Cancer (clinicaltrials.gov)
P2, N=160, Not yet recruiting, Hoffmann-La Roche
New P2 trial • Metastases
|
HER-2 (Human epidermal growth factor receptor 2) • PD-L1 (Programmed death ligand 1) • ER (Estrogen receptor) • CD4 (CD4 Molecule)
|
PD-L1 expression • PGR expression
|
Keytruda (pembrolizumab) • albumin-bound paclitaxel • tobemstomig (RG6139)
over1year
A Study of Tobemstomig Plus Platinum-Based Chemotherapy vs Pembrolizumab Plus Platinum-Based Chemotherapy in Participants With Previously Untreated Non-Small Cell Lung Cancer (clinicaltrials.gov)
P2, N=180, Recruiting, Hoffmann-La Roche
New P2 trial • IO biomarker • Metastases
|
PD-L1 (Programmed death ligand 1)
|
PD-L1 expression
|
Keytruda (pembrolizumab) • carboplatin • paclitaxel • pemetrexed • tobemstomig (RG6139)
almost2years
A Study of RO7247669 Alone or in Combination with Tiragolumab Versus Atezolizumab in Patients with Previously Untreated Locally Advanced or Metastatic Urothelial Bladder Cancer who are Ineligible for Platinum-Containing Chemotherapy (clinicaltrialsregister.eu)
P2, N=240, Ongoing, F. Hoffmann-La Roche Ltd
New P2 trial • Combination therapy • Metastases
|
PD-L1 (Programmed death ligand 1)
|
Tecentriq (atezolizumab) • tiragolumab (RG6058) • tobemstomig (RG6139)
almost2years
A Study Evaluating the Efficacy and Safety of Multiple Immunotherapy-Based Treatment Combinations in Patients With Advanced Liver Cancers (Morpheus-Liver) (clinicaltrials.gov)
P1/2, N=320, Recruiting, Hoffmann-La Roche | Trial completion date: Jul 2025 --> Dec 2025 | Trial primary completion date: Jul 2025 --> Dec 2025
Trial completion date • Trial primary completion date • Metastases
|
PD-L1 (Programmed death ligand 1)
|
Avastin (bevacizumab) • Tecentriq (atezolizumab) • amezalpat (TPST-1120) • Actemra IV (tocilizumab) • tiragolumab (RG6058) • muzastotug (ADG126) • tobemstomig (RG6139)
almost2years
A Study of RO7247669 Alone or in Combination With Tiragolumab vs Atezolizumab in Participants With Untreated Locally Advanced or Metastatic Urothelial Cancer (clinicaltrials.gov)
P2, N=240, Recruiting, Hoffmann-La Roche | Not yet recruiting --> Recruiting
Enrollment open • Combination therapy • Metastases
|
PD-L1 (Programmed death ligand 1)
|
Tecentriq (atezolizumab) • tiragolumab (RG6058) • tobemstomig (RG6139)
almost2years
A Study of RO7247669 Alone or in Combination With Tiragolumab vs Atezolizumab in Participants With Untreated Locally Advanced or Metastatic Urothelial Cancer (clinicaltrials.gov)
P2, N=240, Not yet recruiting, Hoffmann-La Roche
New P2 trial • Combination therapy • Metastases
|
PD-L1 (Programmed death ligand 1)
|
Tecentriq (atezolizumab) • tiragolumab (RG6058) • tobemstomig (RG6139)
2years
A Study Evaluating the Efficacy and Safety of Multiple Immunotherapy-Based Treatment Combinations in Patients With Advanced Liver Cancers (Morpheus-Liver) (clinicaltrials.gov)
P1/2, N=320, Recruiting, Hoffmann-La Roche | Trial completion date: Dec 2024 --> Jul 2025 | Trial primary completion date: Dec 2024 --> Jul 2025
Trial completion date • Trial primary completion date
|
PD-L1 (Programmed death ligand 1)
|
Avastin (bevacizumab) • Tecentriq (atezolizumab) • amezalpat (TPST-1120) • Actemra IV (tocilizumab) • tiragolumab (RG6058) • tobemstomig (RG6139)
over2years
Clinical activity, safety, and PK/PD from the first in human study (NP41300) of RO7247669, a PD1-LAG3 bispecific antibody (ESMO 2022)
Conclusions RO7274669 has a favorable safety profile and has shown encouraging anti-tumor activity in the dose escalation phase. Expansion cohorts in CPI experienced Melanoma and NSCLC as well as CPI naive ESCC are ongoing.
Clinical • P1 data • PK/PD data
|
PD-1 (Programmed cell death 1) • LAG3 (Lymphocyte Activating 3) • PD-L2 (Programmed Cell Death 1 Ligand 2)
|
tobemstomig (RG6139)
over2years
A Study of Multiple Doses of RO7247669 in Participants With Previously Untreated Unresectable or Metastatic Melanoma (clinicaltrials.gov)
P2, N=80, Recruiting, Hoffmann-La Roche | Not yet recruiting --> Recruiting
Enrollment open
|
PD-L1 (Programmed death ligand 1) • BRAF (B-raf proto-oncogene)
|
BRAF mutation • BRAF V600
|
tobemstomig (RG6139)
over2years
A Study of Multiple Doses of RO7247669 in Participants With Previously Untreated Unresectable or Metastatic Melanoma (clinicaltrials.gov)
P2, N=80, Not yet recruiting, Hoffmann-La Roche
New P2 trial
|
PD-L1 (Programmed death ligand 1) • BRAF (B-raf proto-oncogene)
|
BRAF mutation • BRAF V600
|
tobemstomig (RG6139)
over2years
A Study Evaluating the Efficacy and Safety of Multiple Immunotherapy-Based Treatment Combinations in Patients With Advanced Liver Cancers (Morpheus-Liver) (clinicaltrials.gov)
P1/2, N=280, Recruiting, Hoffmann-La Roche | Trial completion date: Jul 2024 --> Dec 2024 | Trial primary completion date: Jul 2024 --> Dec 2024
Trial completion date • Trial primary completion date
|
PD-L1 (Programmed death ligand 1)
|
Avastin (bevacizumab) • Tecentriq (atezolizumab) • amezalpat (TPST-1120) • Actemra IV (tocilizumab) • tiragolumab (RG6058) • SAR439459 • tobemstomig (RG6139)
over2years
A Study of RO7121661 and RO7247669 Compared With Nivolumab in Participants With Advanced or Metastatic Squamous Cell Carcinoma of the Esophagus (clinicaltrials.gov)
P2, N=210, Recruiting, Hoffmann-La Roche | Trial completion date: Oct 2024 --> May 2025 | Trial primary completion date: Oct 2024 --> May 2025
Trial completion date • Trial primary completion date • IO biomarker
|
CD8 (cluster of differentiation 8) • PD-1 (Programmed cell death 1) • LAG3 (Lymphocyte Activating 3) • HAVCR2 (Hepatitis A Virus Cellular Receptor 2) • CD4 (CD4 Molecule)
|
CD8 expression • LAG3 expression
|
Opdivo (nivolumab) • lomvastomig (RG7769) • tobemstomig (RG6139)
3years
A Study Evaluating the Efficacy and Safety of Multiple Immunotherapy-Based Treatment Combinations in Patients With Advanced Liver Cancers (Morpheus-Liver) (clinicaltrials.gov)
P1/2, N=280, Recruiting, Hoffmann-La Roche | Trial completion date: Oct 2024 --> Jul 2024
Clinical • Trial completion date
|
PD-L1 (Programmed death ligand 1)
|
Avastin (bevacizumab) • Tecentriq (atezolizumab) • amezalpat (TPST-1120) • Actemra IV (tocilizumab) • tiragolumab (RG6058) • SAR439459 • tobemstomig (RG6139)
over3years
A Study Evaluating the Efficacy and Safety of Multiple Immunotherapy-Based Treatment Combinations in Patients With Advanced Liver Cancers (Morpheus-Liver) (clinicaltrials.gov)
P1/2, N=280, Recruiting, Hoffmann-La Roche | N=100 --> 280 | Trial completion date: Jul 2024 --> Oct 2024 | Trial primary completion date: Oct 2021 --> Jul 2024
Clinical • Enrollment change • Trial completion date • Trial primary completion date
|
PD-L1 (Programmed death ligand 1)
|
Avastin (bevacizumab) • Tecentriq (atezolizumab) • amezalpat (TPST-1120) • Actemra IV (tocilizumab) • tiragolumab (RG6058) • SAR439459 • tobemstomig (RG6139)
over3years
A Study of RO7121661 and RO7247669 Compared With Nivolumab in Participants With Advanced or Metastatic Squamous Cell Carcinoma of the Esophagus (clinicaltrials.gov)
P2, N=255, Recruiting, Hoffmann-La Roche | Not yet recruiting --> Recruiting
Clinical • Enrollment open • IO biomarker
|
CD8 (cluster of differentiation 8) • PD-1 (Programmed cell death 1) • LAG3 (Lymphocyte Activating 3) • HAVCR2 (Hepatitis A Virus Cellular Receptor 2) • CD4 (CD4 Molecule)
|
CD8 expression • LAG3 expression
|
Opdivo (nivolumab) • lomvastomig (RG7769) • tobemstomig (RG6139)
over3years
A Study of RO7121661 and RO7247669 Compared With Nivolumab in Participants With Advanced or Metastatic Squamous Cell Carcinoma of the Esophagus (clinicaltrials.gov)
P2, N=255, Not yet recruiting, Hoffmann-La Roche
Clinical • New P2 trial • IO biomarker
|
CD8 (cluster of differentiation 8) • PD-1 (Programmed cell death 1) • LAG3 (Lymphocyte Activating 3) • HAVCR2 (Hepatitis A Virus Cellular Receptor 2) • CD4 (CD4 Molecule)
|
CD8 expression • LAG3 expression
|
Opdivo (nivolumab) • lomvastomig (RG7769) • tobemstomig (RG6139)
4years
A Study Evaluating the Efficacy and Safety of Multiple Immunotherapy-Based Treatment Combinations in Patients With Advanced Liver Cancers (Morpheus-Liver) (clinicaltrials.gov)
P1/2; N=100; Recruiting; Sponsor: Hoffmann-La Roche
New P1/2 trial
|
PD-L1 (Programmed death ligand 1)
|
Avastin (bevacizumab) • Tecentriq (atezolizumab) • amezalpat (TPST-1120) • Actemra IV (tocilizumab) • tiragolumab (RG6058) • SAR439459 • tobemstomig (RG6139)
Share via
